Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%
Market cap
$13.8B
P/E
34.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
22.24 22.13 25.79 15.00

+8 more quarters

P/S ratio
5.52 5.06 5.77 6.92
P/FCF ratio
11.39 11.44 12.51 11.62
P/Operating CF
38.10 42.40 36.82 48.14
P/B ratio
63.95 34.77 165.22 17.06
EV/Sales
6.67 6.27 7.72 7.57
EV/EBITDA
15.43 15.27 19.20 11.46
EV/FCF
13.76 14.17 16.72 12.72
Current Ratio
2.71 2.76 4.66 1.59
Net Debt/EBITDA
5.93 8.28 (31.07) 3.37
Debt/Equity
14.95 9.76 43.89 3.00
Earnings Yield
4.50% 4.52% 3.88% 6.67%
Free Cash Flow Yield
8.78% 8.74% 7.99% 8.60%
Free Cash Flow per Share
2.02 1.49 (1.93) 5.33
Book value per Share
1.22 1.86 0.41 4.30
Free Cash Flow
236.72 176.34 (231.27) 624.44
EV/EBIT
18.58 18.48 22.98 12.76
Other line items

Show all line items

Columns are period end dates